One additional PR was achieved in a patient with heavily pretreated CCA that was PD-L1 negative, mismatch repair proficient, with a tumor mutational burden of 10 mut/Mb; he had received six prior lines of systemic therapy before study enrollment (Fig. 2B). The gene discussed is CD274; the disease is neoplasm.